Geographic expansion Leverage the nationwide clinic footprint (AZ, CO, TX, MN, WA, IL, FL, NV) and recent Utah entry to position bundled regional support packages, telemedicine follow-ups, and cross-state referral networks to accelerate patient acquisition and clinic partnerships.

Integrated therapies Opportunity to upsell and bundle ketamine infusion with NAD+ therapy and Spravato options across clinics, targeting existing patients seeking comprehensive mood and pain management solutions.

Strategic partnerships Capitalize on prior integration with Ketamine Infusion Centers and Delic Holdings to pursue co-marketing, provider-directory collaborations, and referral arrangements with affiliated networks to expand reach.

Digital outreach Current tech stack includes Google Ads, Klaviyo, and WordPress; optimize paid search and email marketing to nurture inquiries, improve lead quality, and drive appointment scheduling for new and expanding clinics.

Financial positioning Revenue range indicates growing but mid-scale operation; target mid-market medical practice buyers and private equity interests seeking scalable, evidence-based psychedelic therapy platforms with multi-location presence.